Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H6O2 |
Molecular Weight | 122.1213 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=CC=C1
InChI
InChIKey=WPYMKLBDIGXBTP-UHFFFAOYSA-N
InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)
Molecular Formula | C7H6O2 |
Molecular Weight | 122.1213 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.viacheminc.com/product/ammonium-benzoate/https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_015.pdfCurator's Comment: description was created based on several sources, including:
http://apps.who.int/medicinedocs/en/d/Jh2918e/24.2.html | http://www.wikidoc.org/index.php/Benzoic_acid | http://www.who.int/ipcs/publications/cicad/cicad26_rev_1.pdf | https://www.ewg.org/skindeep/ingredient/700679/BENZOIC_ACID/
Sources: http://www.viacheminc.com/product/ammonium-benzoate/https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_015.pdf
Curator's Comment: description was created based on several sources, including:
http://apps.who.int/medicinedocs/en/d/Jh2918e/24.2.html | http://www.wikidoc.org/index.php/Benzoic_acid | http://www.who.int/ipcs/publications/cicad/cicad26_rev_1.pdf | https://www.ewg.org/skindeep/ingredient/700679/BENZOIC_ACID/
Benzoic acid is a natural ingredient occurring in many foodstuffs and in plant extracts. Benzoic acid, its salts and esters are used as preservatives in cosmetic products, with a maximum concentration of 0.5 %. Benzoic acid and sodium benzoate are on the FDA list of substances that are generally recognized as safe (GRAS). Both may be used as antimicrobial agents, flavouring agents and as adjuvants with a current maximum level of 0.1% in food. Benzoic acid is a constituent of Whitfield Ointment, which is used for the treatment of fungal skin diseases such as tinea, ringworm, and athlete's foot. Adverse effect of Whitfield Ointment: occasionally, a localized mild inflammatory response occurs.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map00010 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1785916 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Whitfield’s ointment Approved UseTreatment of mild superficial fungal infections, particularly tinea pedis, tinea corporis and, occasionally, tinea capitis. |
|||
Curative | Whitfield’s ointment Approved UseTreatment of mild superficial fungal infections, particularly tinea pedis, tinea corporis and, occasionally, tinea capitis. |
|||
Primary | UCEPHAN Approved UseSodium benzoate and sodium phenylacetate combination is used to treat a condition caused by too much ammonia in the blood (hyperammonemia). Launch Date1987 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
99.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1804654/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
BENZOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
104.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1804654/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
BENZOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1804654/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
BENZOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
[Influence of sodium benzoate, p-aminobenzoic acid and ammonium benzoate on the lethal doses of procaine and lidocaine in male rats (author's transl)]. | 1973 Dec |
|
Studies of aflatoxins in Chiang Mai, Thailand. | 1992 Apr |
|
[Studies on the infrared and fluorescence spectra of europium lanthanum-benzoate complexes]. | 1999 Aug |
|
Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries. | 2001 |
|
Novel retinoidal tropolone derivatives. Bioisosteric relationship of tropolone ring with benzoic acid moiety in retinoid structure. | 2001 Apr |
|
In vivo 1H magnetic resonance spectroscopic measurement of brain glycine levels in nonketotic hyperglycinemia. | 2001 Apr |
|
Non-ionic micellar affinity capillary electrophoresis for analysis of interactions between micelles and drugs. | 2001 Feb |
|
Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure. | 2001 Feb |
|
Genetic manipulation of 6-phosphofructo-1-kinase and fructose 2,6-bisphosphate levels affects the extent to which benzoic acid inhibits the growth of Saccharomyces cerevisiae. | 2001 Feb |
|
Convenient synthesis of 4,6-di-O-benzyl-myo-inositol and myo-inositol 1,3,5-orthoesters. | 2001 Feb 15 |
|
Dansylation of hydroxyl and carboxylic acid functional groups. | 2001 Feb 26 |
|
Characterization of the FAD-containing N-methyltryptophan oxidase from Escherichia coli. | 2001 Feb 6 |
|
Cinnamic acid is a precursor of benzoic acids in cell cultures of Hypericum androsaemum L. but not in cell cultures of Centaurium erythraea RAFN. | 2001 Jan |
|
The chlorobenzoate dioxygenase genes of Burkholderia sp. strain NK8 involved in the catabolism of chlorobenzoates. | 2001 Jan |
|
Alternative pathway therapy for urea cycle disorders: twenty years later. | 2001 Jan |
|
Expression of 2-halobenzoate dioxygenase genes (cbdSABC) involved in the degradation of benzoate and 2-halobenzoate in Burkholderia sp. TH2. | 2001 Jan 10 |
|
Substrate specificity of human cathepsin D using internally quenched fluorescent peptides derived from reactive site loop of kallistatin. | 2001 Jan 12 |
|
Polyacrylamides as hydrophilic selectors in non-aqueous capillary electrophoresis. | 2001 Jan 5 |
|
Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. | 2001 Jul |
|
A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus. | 2001 Jul 6 |
|
m-Iodobenzoic acid complexes with selected metals: molecular structure and antimicrobial activity. | 2001 Jun |
|
[Kinetics of in vitro drug release from chitosan and N-alkyl chitosan membranes]. | 2001 Mar |
|
A calorimetrically based method to convert toxic compounds into poly-3-hydroxybutyrate and to determine the efficiency and velocity of conversion. | 2001 Mar |
|
High-performance liquid chromatographic method development and validation for the simultaneous quantitation of naproxen sodium and pseudoephedrine hydrochloride impurities. | 2001 Mar |
|
Aerobic and anoxic biodegradation of benzoate: stability of biodegradative capability under endogenous conditions. | 2001 Mar |
|
Enhanced biodegradation of petrochemical wastewater using ozonation and BAC advanced treatment system. | 2001 Mar |
|
ATR-FTIR spectroscopic investigations on the effect of solvents on the permeation of benzoic acid and salicylic acid through silicone membranes. | 2001 Mar 23 |
|
Cytosolic xanthine oxidoreductase mediated bioactivation of ethanol to acetaldehyde and free radicals in rat breast tissue. Its potential role in alcohol-promoted mammary cancer. | 2001 Mar 7 |
|
Tyrosine and phenylalanine catabolism by Lactobacillus cheese flavor adjuncts. | 2001 May |
|
Analysis for organic residues from aids to polymerization used to make plastics intended for food contact. | 2001 May |
|
Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals. | 2001 May |
|
Electric field analysis on the improved skin concentration of benzoate by electroporation. | 2001 May 21 |
Sample Use Guides
Oral/Parenteral Toxicity:
oral-rat LD50 825 mg/kg
oral-mouse LD50 235 mg/kg
intravenous-rabbit LDLo 400 mg/kg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20193780
Colorimetric titration of protein thiol groups revealed that in the presence of ammonium benzoate (0.12 mM), the two muteins were not oxidized at cysteines whereas in the wild-type enzyme, one thiol group was derivatized.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:08:03 GMT 2023
by
admin
on
Fri Dec 15 15:08:03 GMT 2023
|
Record UNII |
8SKN0B0MIM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
JECFA EVALUATION |
INS-210
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
FDA ORPHAN DRUG |
11385
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
FDA ORPHAN DRUG |
77993
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
NDF-RT |
N0000175807
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
EPA PESTICIDE CODE |
9101
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
NDF-RT |
N0000175806
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
CFR |
21 CFR 310.527
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
LOINC |
75065-3
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
CFR |
21 CFR 573.210
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
FDA ORPHAN DRUG |
365712
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-210
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
||
|
CFR |
21 CFR 184.1021
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C45678
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
CONCEPT | Industrial Aid | ||
|
8SKN0B0MIM
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
70589
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
ALTERNATIVE | |||
|
30746
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
100000090433
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
BENZOIC ACID
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | Description: Colourless, light, feathery crystals or a white, microcrystalline powder; odour, characteristic, faint. Solubility: Slightly soluble in water; freely soluble in ethanol (~750 g/l) TS, ether R. Category: Dermatological agent. Storage: Benzoic acid should be kept in a well-closed container. Definition: Benzoic acid contains not less than 99.0% and not more than 100.5% of C7H6O2, calculated with reference to the anhydrous substance. | ||
|
8SKN0B0MIM
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
149
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
C61646
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
D019817
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
CHEMBL541
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
704
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
743
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
m2363
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | Merck Index | ||
|
18989
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
1055002
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
243
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
DTXSID6020143
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
16150
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
BENZOIC ACID
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
DB03793
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
SUB12469MIG
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
65-85-0
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
200-618-2
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY | |||
|
4664
Created by
admin on Fri Dec 15 15:08:03 GMT 2023 , Edited by admin on Fri Dec 15 15:08:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
MIC 320 mg/L for ATCC 700392 and ATCC 700824 strains of H. pylori.
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
in horse urine
URINE
|
||
|
PARENT -> METABOLITE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
Correction factors: for the calculation of contents, multiply the peak areas by 4.0
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
http://apps.who.int/phint/pdf/b/Jb.6.1.49.pdf
|